Aarti Drugs Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/okbdj44cwwtgf3dlp2kt70e5.pdf

Key Takeaways


Revenue & Margin Bridge

Adhish Patil: "So that is the reason why we have taken a call to roll back that process to the old one where, in fact, last 9 months, we have been suffering losses because of the quality issues for that chlorosulfonation -- the newer chlorosulfonation line, which has been rolled back. And now all those losses have been already curtailed."

Greenfield Projects: The Margin Path

Adhish Patil: "We can say that if the situation what is there now, if it remains like that for next 2 to 3 years, we should definitely start inching towards 15% EBITDA margins, frankly speaking."

US FDA & Export Opportunity

Adhish Patil: "When it comes to API manufacturing facilities for US FDA, so there are very limited facilities which manufacture APIs for US FDA. In Formulation, it might be slightly different, but in API space -- and the main trick is to manufacture that product year-round. Means if there are more changeovers in the plant, obviously, the EBITDA margins get a hit because of changeover."

Segment & Product Dynamics


Volume & Value Growth Outlook

Adhish Patil: "Yes. So volume growth, we will definitely try for 15% to 20%, no doubt about that. We'll try to -- with the help of salicylic acid, I hope we'll get to those numbers."

Guidance & Commitments

CommitmentSpecificsTimeline
Tarapur greenfield ramp-upProduction of 500-plus tons per monthBy end of March 2025
Sequential capacity ramp1,600 metric tons per monthBy end of FY26
Sayakha trial productionTrial production to commenceFebruary 2025
Sayakha revenue visibilitySales from greenfield products visible in financialsQ1 FY26
Formulation capex completionFacility update completedEnd of FY25
Formulation brownfield capacity contributionRevenues from 30% additional capacity start kicking inQ1 FY26
Chlorosulfonation margin improvementSlight gross margin improvement beginsMarch quarter (Q4 FY25)
Chlorosulfonation capacity restorationScale back to original planned levels with old process3-4 months
US FDA plant meaningful revenue contributionMaterial revenue from US marketFY27 (not FY26)
Solar plant operationCommence operationEnd of H1 FY26
FY26 EBITDA margin target13-14% EBITDA marginsFY26
Long-term EBITDA margin trajectoryInching toward 15%2-3 years, assuming current conditions hold
Consolidated revenue ambitionRoughly ₹4,000 CrIn 3 years' time
Volume growth target15-20% volume growthNext year (FY26)

Key Metrics

MetricQ3 FY25
Revenue₹568 cr, decline of 6% YoY from ₹607 cr
Gross profit₹207 cr, up 7% YoY from ₹202 cr
Formulation revenue₹48.6 cr, with 47% from exports
API price variance (YoY)-2% to -2.5% on an average basis
API price variance (sequential, FY25)-5% to -7% price drop over the financial year
EBITDA margin guidance (FY26)13% to 14%
EBITDA margin aspiration (2-3 years)~15% if current conditions persist
Revenue aspiration (3 years)~₹4,000 cr on a consolidated basis
Volume growth target (FY26)15% to 20%
Capex incurred (9M FY25)₹136 cr
Capex guidance (FY25 full year)~₹200 cr
Tarapur greenfield production ramp-up target500-plus tons per month by end of March 2025
Total capacity ramp-up target1,600 metric tons per month by end of FY26
Antidiabetic segment revenue share (standalone)12% to 13%
US FDA plant revenue potential (current)₹70 cr to ₹80 cr per annum